Updates on CAR T-Cells for Large B-Cell Lymphoma
Author Information
Author(s): Saleh Khalil, Khalife Nadine, Arbab Ahmadreza, Khoury Rita, Chahine Claude, Ibrahim Rebecca, Tikriti Zamzam, Masri Nohad, Hachem Mohamad, Le Cesne Axel
Primary Institution: Gustave Roussy Cancer Campus
Conclusion
CD19-targeting CAR T-cells have significantly improved treatment outcomes for patients with large B-cell lymphoma, but many still experience relapse.
Supporting Evidence
- Three CAR T-cells have been approved by the FDA for treating relapsed large B-cell lymphoma.
- Overall response rates for these CAR T-cells range from 52% to 82%.
- 30% to 40% of patients may be cured with a single infusion of CAR T-cells.
- 60% to 70% of patients relapse after CAR T-cell treatment.
Takeaway
This study talks about special immune cells called CAR T-cells that help treat a type of blood cancer called large B-cell lymphoma. They work well for some people, but many still get sick again after treatment.
Methodology
This review summarizes clinical efficacy and safety profiles of three FDA-approved CAR T-cells for treating relapsed or refractory large B-cell lymphoma.
Limitations
The review is based on existing studies and may not cover all recent developments in CAR T-cell therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website